Switzerland : Novartis provides update on BELINDA study investigating Kymriah as second-line treatment in aggressive B-cell non-Hodgkin lymphoma

Phase III BELINDA study did not meet primary endpoint of event-free survival for patients with aggressive B-cell non-Hodgkin lymphoma who had primary refractory disease or who relapsed within 12 months [...]